Rollins Inc.
ROL
$33.45
-1.30%
Rollins, Inc. is a global leader in route-based pest control services, operating primarily through its flagship Orkin brand across the United States, Canada, and a growing international footprint spanning Europe, the Middle East, Africa, Australia, and Latin America. The company is a defensive, recurring-revenue compounder in the Specialty Business Services industry, distinguished by its near-national Orkin coverage, a portfolio of complementary brands serving alternative sales channels, and a business model built on high-retention residential and commercial subscription routes. The current investor narrative has shifted sharply negative: despite steady mid-single-digit organic growth and continued bolt-on acquisition activity, the stock has de-rated violently as investors question whether the premium multiple long afforded to pest control's perceived recession-resistance is justified against decelerating earnings growth, rising interest expense, and a payout ratio that has crept toward the high end of its historical range. The debate now centers on whether this is a temporary sentiment-driven dislocation in a high-quality franchise or the beginning of a structural re-rating as growth normalizes toward the mid-single digits and the market reprices the sector's 'bond-proxy' characteristics in a higher-rate environment.…
ROL
Rollins Inc.
$33.45
ROL 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Rollins Inc.'s 12-month outlook, with a consensus price target around $40.76 and implied upside of +21.9% versus the current price.
Average Target
$40.76
0 analysts
Implied Upside
+21.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$27 - $66
Analyst target range
Coverage is broad with 17 analysts, but sentiment is decidedly cautious. The consensus recommendation is 'hold' with a mean rating of 2.58 (on a scale where lower is more bullish), and the average target price of $40.76 implies roughly +21.9% upside from the current $33.45. That upside is meaningful but should be read in context: it reflects recovery from a deeply depressed base rather than conviction in a near-term catalyst. The distribution leans neutral-to-bearish, with recent actions showing downgrades — Piper Sandler moved from Overweight to Neutral on September 24, and Argus Research cut from Buy to Hold on August 5 — while Wells Fargo maintains an Underweight rating. Morgan Stanley and Barclays remain Overweight, creating a split house view.
The target range is exceptionally wide, from a low of $27.00 to a high of $66.00 — a spread of more than 140% around the average, which signals high uncertainty and low conviction among analysts. The high target of $66.00 (roughly the 52-week high) assumes a full recovery in sentiment, multiple re-expansion back toward historical premium levels, and reacceleration in organic growth; it effectively prices in a return to the pre-selloff narrative. The low target of $27.00 (below the 52-week low of $29.29) prices in continued margin compression, further multiple contraction, and possibly a recession-driven slowdown in residential pest control demand. The consensus EPS estimate of $1.67 and revenue estimate of $5.43 billion imply modest growth expectations, and the wide dispersion of targets against a 'hold' consensus suggests analysts see the stock as fairly valued-to-cheap but lack a clear catalyst to turn bullish — a setup that typically produces range-bound, volatile trading until fundamentals provide direction.
Bulls vs Bears: ROL Investment Factors
The bear case currently holds stronger evidence: the stock is in a confirmed downtrend (-54.74% max drawdown, trading at 11.3% of its 52-week range), gross margins have compressed ~400bps, revenue growth has decelerated to 7.91%, and analysts have been downgrading with a 'hold' consensus. The bull case rests on quality fundamentals — 14.0% net margin, 38.3% ROE, $619.2 million FCF — and a forward PE of 26.10x that is far less demanding than the 55.06x trailing figure. The single most important tension is whether the margin compression is cyclical (cost inflation, acquisition integration) or structural: if gross margins stabilize back toward 52-54%, the current PS of 7.73x could mark a value floor; if they keep sliding, the premium-multiple thesis is permanently broken. Until there is evidence of a durable base and margin stabilization, the weight of evidence favors caution over conviction buying.
Bullish
- Forward PE compresses to 26.1x: While the trailing PE of 55.06x looks extreme, the forward PE of 26.10x against a consensus EPS estimate of $1.67 implies the market is pricing earnings roughly doubling from the trailing base. For a business still generating 7.91% revenue growth and a 14.0% net margin, that forward multiple is far more defensible than the headline trailing figure suggests.
- Recurring revenue model with 7.91% growth: Q2 2026 revenue of $1.079 billion grew 7.91% year-over-year, and residential pest control alone contributes $485.8 million (45% of total) on subscription-style routes with high retention. This is a defensive, non-discretionary service with visible cash flows, not a cyclical business dependent on a single customer or contract.
- Strong profitability and returns: Net margin of 14.0%, operating margin of 19.30%, and ROE of 38.3% demonstrate a high-quality, asset-light franchise. Free cash flow TTM of $619.2 million converts at roughly 96% of operating cash flow, funding both the 1.13% dividend and bolt-on acquisitions internally.
- Analyst target implies 21.9% upside: The average target price of $40.76 across 17 analysts implies roughly +21.9% from the current $33.45, with Morgan Stanley and Barclays maintaining Overweight ratings. Even the consensus 'hold' rating (mean 2.58) reflects valuation caution rather than a fundamental breakdown thesis.
Bearish
- Falling knife with -54.74% drawdown: The stock is down 39.45% over one year and 43.31% YTD, sitting at just 11.3% of its 52-week range ($29.29-$66.14) and roughly 49% below its high. With a max drawdown of -54.74% and no durable base forming, this is a sustained downtrend, not a simple pullback.
- Gross margin compression of ~400bps: Gross margin fell to 49.73% in Q2 2026 from 53.79% a year earlier and 54.44% in Q3 2025, while operating margin dropped to 18.67% from 19.84%. For a business with historically stable 52-54% gross margins, this deterioration directly undermines the premium-multiple thesis.
- Growth decelerating to mid-single digits: Revenue growth stepped down from 10.2% in Q1 2026 to 7.91% in Q2 2026, and the trend implies a transition from premium grower to steady mid-single-digit compounder. A PEG ratio of 4.07 shows the stock is not cheap even on a growth-adjusted basis at this trajectory.
- Thin FCF yield and liquidity strain: FCF TTM of $619.2 million against a $29.06 billion market cap yields just ~2.1%, while the current ratio of 0.602 means current liabilities far exceed current assets. Rising interest expense ($9.39 million in Q2 2026 vs. $7.38 million a year prior) adds further strain.
ROL Technical Analysis
Rollins is in a pronounced, sustained downtrend that has erased more than a third of shareholder value over the trailing year, with a 1-year price change of -39.45% and a YTD decline of -43.31%. At the current price of $33.45, the stock sits at just 11.3% of its 52-week range (low of $29.29, high of $66.14), meaning it is trading in the bottom decile of its annual band and roughly 49% below its high. This positioning is characteristic of a falling-knife setup rather than a value opportunity — the stock has lost more than half its value from peak (max drawdown of -54.74%), and there is no evidence yet of a durable base forming. The relative strength figures underscore the severity: -54.98% versus the S&P 500 over one year and -55.24% YTD, a catastrophic underperformance that signals institutional distribution rather than a simple pullback.
Short-term momentum remains negative but is showing tentative signs of stabilization. The 1-month change of -23.86% and 3-month change of -25.85% confirm that the selling pressure has been relentless and, critically, the pace has not decelerated relative to the 6-month decline of -39.18% — the stock is still making lower lows into October. However, the last two weeks show a modest bounce from the $29.69 low on October 5 to $33.45, a roughly 12.7% off-bottom recovery, and the 1-month relative strength of -1.46% versus SPY's +1.22% indicates the underperformance gap is narrowing. This divergence — a still-negative 1-month trend against a sharp off-bottom rally — could signal either a short-term mean-reversion bounce within a larger downtrend or the early stages of capitulation exhaustion; volume of 5.47 million shares suggests elevated turnover consistent with forced selling or bottom-fishing interest.
Key technical levels are clearly defined. Support rests at the 52-week low of $29.29, with the October 5 close of $29.69 acting as the immediate floor; a breakdown below this zone would open the door to a fresh leg lower and confirm the downtrend's persistence. Resistance sits at the 52-week high of $66.14, but more relevant near-term resistance is the $38-$40 area where the July breakdown accelerated. A breakout above $40 would be the first meaningful signal of trend reversal, while a failure at current levels and a retest of $29 would reinforce the bearish structure. The beta of 0.731 is a critical risk-management input: despite the violent drawdown, Rollins is theoretically ~27% less volatile than the market, meaning the decline is driven by idiosyncratic de-rating rather than broad market beta — position sizing should account for the fact that this is a stock-specific repricing, not a market-correlated move.
Beta
0.73
0.73x market volatility
Max Drawdown
-54.7%
Largest decline past year
52-Week Range
$29-$66
Price range past year
Annual Return
-39.4%
Cumulative gain past year
| Period | ROL Return | S&P 500 |
|---|---|---|
| 1m | -0.2% | +0.2% |
| 3m | -25.8% | +2.9% |
| 6m | -39.2% | +8.4% |
| 1y | -39.4% | +14.9% |
| ytd | -43.3% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ROL Fundamental Analysis
Revenue growth remains intact but is decelerating. Q2 2026 revenue of $1.079 billion grew 7.91% year-over-year versus $999.5 million in Q2 2025, a solid but unspectacular pace for a route-based compounder. The multi-quarter trend shows a clear deceleration: Q1 2026 revenue of $906.4 million grew 10.2% over Q1 2025's $822.5 million, while Q4 2025's $912.9 million grew 9.7% over Q4 2024's $832.2 million — so the Q2 print marks a step down in the growth trajectory. Segment mix shows residential revenues of $485.8 million (45% of the total) as the largest driver, followed by commercial at $347.9 million (32%) and termite/ancillary at $234.2 million (22%), with franchise and other contributing a combined ~1%. The growth trend implies the investment case is transitioning from a premium-growth story to a steady-but-unexciting mid-single-digit grower, which is precisely the profile that struggles to justify a premium multiple.
Profitability is robust but margins are compressing. Q2 2026 net income of $143.9 million on $1.079 billion revenue produced a net margin of 13.34%, down from 14.16% in Q2 2025 and well below Q3 2025's 15.94%. Gross margin followed the same path: 49.73% in Q2 2026 versus 53.79% a year earlier and 54.44% in Q3 2025, a roughly 400-basis-point compression that is material for a business with historically stable ~52-54% gross margins. Operating margin of 18.67% in Q2 2026 compares unfavorably to 19.84% in Q2 2025 and 21.93% in Q3 2025, and the trailing operating margin of 19.30% masks the deterioration. The company remains solidly profitable — net margin of 14.0% and ROE of 38.3% are strong — but the direction of travel is negative, with cost inflation, acquisition integration, and rising interest expense ($9.39 million in Q2 2026 versus $7.38 million a year prior) all weighing on the bottom line.
Balance sheet and cash flow are adequate but not without strain. Debt-to-equity of 0.755 is moderate, and interest coverage of ~21x (Q2 2026 operating income of $201.4 million versus $9.39 million interest expense) remains comfortable. However, the current ratio of 0.602 is a red flag for liquidity — current liabilities exceed current assets by a wide margin, a structural feature of route-based businesses that collect receivables quickly (days sales outstanding of ~24) but still warrants monitoring. Free cash flow TTM of $619.2 million against a $29.06 billion market cap implies an FCF yield of just ~2.1%, thin for a company with a 1.13% dividend yield and a payout ratio of 62.3%. The company is generating enough cash to fund operations and dividends internally, but the $116.8 million of Q2 2026 acquisitions and $52.0 million of debt repayment show it is also leaning on external capital allocation; with capex light at $6.4 million in Q2, the FCF conversion is healthy (FCF/OCF of ~96%), but the low FCF yield leaves little margin for error if growth slows further.
Quarterly Revenue
$1.1B
2026-06
Revenue YoY Growth
+7.9%
YoY Comparison
Gross Margin
49.7%
Latest Quarter
Free Cash Flow
$619169000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ROL Overvalued?
Because Rollins is profitable (Q2 2026 net income of $143.9 million, TTM EPS positive), the PE ratio is the appropriate primary metric. The trailing PE of 55.06x is elevated in absolute terms, but the forward PE of 26.10x tells a very different story — the gap implies the market expects earnings to roughly double, consistent with the analyst consensus EPS estimate of $1.67 versus the trailing figure. That forward multiple is far more reasonable and suggests the selloff has compressed the valuation to a level where forward earnings growth is being priced at a discount to the trailing premium. However, the PEG ratio of 4.07 signals that even on a growth-adjusted basis, the stock is not cheap relative to its expected earnings trajectory.
Against its own sector and peer context, Rollins trades at a significant premium on most metrics. The PS ratio of 7.73x and EV/Sales of 4.41x are rich for a business growing revenue at ~8%, and the EV/EBITDA of 35.12x is steep for a services company with ~19% operating margins. The PB ratio of 21.14x reflects the asset-light route-based model but is extreme in absolute terms. The premium is partially justified by the quality of the franchise — recurring revenue, high retention, and a dominant Orkin brand — but with gross margins compressing and growth decelerating, the market is increasingly unwilling to pay up. The dividend yield of 1.13% and payout ratio of 62.3% offer modest income support but are not enough to anchor the valuation.
Historically, Rollins has traded in a PE band roughly between 35x and 65x, with the trailing PE of 55.06x sitting in the upper-middle of that range despite the stock being down 39% over the year — a function of earnings having grown into the multiple even as the price collapsed. The PS ratio of 7.73x, however, is near the low end of its historical range (which has run from ~18x to ~32x in recent quarters per the historical ratios data), a stark divergence that reflects the severity of the price decline relative to revenue. This suggests the market is pricing in either margin deterioration or a permanent de-rating of the sector's growth premium; if margins stabilize, the current PS level could represent a value opportunity, but the historical context warns that the stock is not yet at a clear valuation floor.
PE
55.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 35x~66x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
35.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on margin erosion and liquidity. Gross margin fell to 49.73% in Q2 2026 from 53.79% a year earlier, a ~400bps compression that directly threatens the earnings base, while operating margin slipped to 18.67% from 19.84%. The current ratio of 0.602 is a genuine liquidity flag — current liabilities exceed current assets by a wide margin — and interest expense rose to $9.39 million from $7.38 million year-over-year, consuming a growing share of operating income. With FCF yield at just ~2.1% and a payout ratio of 62.3%, there is limited cushion if growth slows further or acquisition integration costs escalate.
Market and competitive risks are dominated by valuation compression. The trailing PE of 55.06x, PS of 7.73x, EV/EBITDA of 35.12x, and PB of 21.14x all represent premiums that require continued growth and margin stability to justify. The beta of 0.731 means the -39.45% one-year decline is idiosyncratic de-rating, not market-driven — a signal that investors are repricing the sector's 'bond-proxy' characteristics in a higher-rate environment. Analyst downgrades (Piper Sandler to Neutral, Argus to Hold, Wells Fargo Underweight) and a 140%+ target dispersion ($27-$66) reflect low conviction and the risk of further multiple contraction if the next earnings print disappoints.
The worst-case scenario is a continued margin slide combined with a residential demand slowdown, triggering another leg of analyst downgrades and multiple compression. In that chain, the stock could retest and break its 52-week low of $29.29, with the analyst low target of $27.00 sitting below it — implying roughly -19% from the current $33.45 to $27.00, and a full retest of the -54.74% max drawdown would be far more severe from the peak. A realistic adverse case is a decline to the $27-$29 zone (-13% to -19%), with the risk of a deeper move if gross margins fall below 48% and forward EPS estimates of $1.67 are cut.